Jayne Juvan and Dan McClain of Tucker Ellis LLP discuss the slowdown in M&A transactions, in light of the rollout of tariffs, and ways to bridge the gap through contingent consideration where some of ...

Following a review process conducted with the assistance of its legal and financial advisors, the Kronos Bio Board of ...

At the heart of the acquisition is Regulus’ farabursen, an miRNA-targeting oligonucleotide in early-stage development for ...

each pursuant to the contingent value rights agreement (the “CVR Agreement”). Following a review process conducted with the assistance of its legal and financial advisors, the Kronos Bio Board ...

Novartis has signed an agreement to acquire US-based Regulus Therapeutics and its oligonucleotide, farabursen.

Novartis to acquire Regulus for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right, for a total equity value of up to ...

Novartis Acquires Regulus Therapeutics in $1.7 Billion Deal for ADPKD Treatment ...

Kronos Bio said it has agreed to be acquired by Concentra Biosciences at 57 cents per share and contingent rights for proceeds from sales of its product candidates.

The Scheme to Promote Manufacturing of Electric Passenger Cars in India, dubbed the ‘Tesla Policy’, was seen as part of New ...